Why insider trading matters?
When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2022-08-05 | Invus US Partners LLC | 10%-Owner, Director | Buy | 147,390 | $2.50 | $368,475 | No |
| 2022-08-05 | Artal International S.C.A. | 10%-Owner, Director | Buy | 2,426,070 | $2.50 | $6,065,175 | No |
| 2022-08-01 | Artal International S.C.A. | 10%-Owner, Director | Buy | 16,173,800 | $2.50 | $40,434,500 | No |
| 2022-08-01 | DEBBANE RAYMOND | Director | Buy | 982,600 | $2.50 | $2,456,500 | No |
| 2021-03-15 | Tessmer James F | VP, Finance & Accounting | Sell | 22,912 | $6.92 | $158,440 | Yes |
| 2020-12-16 | Artal International S.C.A. | 10%-Owner, Director | Buy | 10,937,500 | $3.20 | $35,000,000 | No |
| 2020-12-16 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 10,937,500 | $3.20 | $35,000,000 | No |
| 2019-09-18 | COATS LONNEL | President and CEO | Buy | 50,000 | $3.10 | $155,000 | No |
| 2019-09-18 | Santini Alexander A | EVP and CCO | Buy | 4,500 | $3.36 | $15,115 | No |
| 2019-09-17 | COATS LONNEL | President and CEO | Buy | 50,000 | $3.13 | $156,403 | No |
| 2019-09-16 | DEBBANE RAYMOND | Director | Buy | 103,042 | $2.69 | $277,591 | No |
| 2019-09-13 | DEBBANE RAYMOND | Director | Buy | 197,473 | $2.40 | $474,760 | No |
| 2019-09-16 | SOBECKI CHRISTOPHER J | Director | Buy | 25,000 | $2.55 | $63,718 | No |
| 2019-09-13 | SOBECKI CHRISTOPHER J | Director | Buy | 99,249 | $2.41 | $238,750 | No |
| 2019-08-19 | COATS LONNEL | President and CEO | Buy | 40,000 | $1.35 | $54,029 | No |
| 2019-08-02 | Tessmer James F | VP, Finance & Accounting | Buy | 10,000 | $1.14 | $11,400 | No |
| 2019-08-02 | BARKER SAM L | Director | Buy | 24,000 | $1.18 | $28,200 | No |
| 2018-06-28 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 182,838 | $12.51 | $2,287,377 | No |
| 2018-06-25 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 253,725 | $12.99 | $3,295,173 | No |
| 2018-06-21 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 72,973 | $13.29 | $970,045 | No |
| 2018-06-18 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 45,784 | $12.98 | $594,399 | No |
| 2018-06-12 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 235,396 | $12.80 | $3,014,123 | No |
| 2018-06-08 | Tessmer James F | VP, Finance & Accounting | Sell | 10,000 | $12.91 | $129,076 | Yes |
| 2018-06-07 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 325,639 | $12.58 | $4,095,065 | No |
| 2018-06-04 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 416,481 | $12.01 | $5,002,667 | No |
| 2018-05-30 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 433,378 | $9.94 | $4,306,418 | No |
| 2018-05-23 | Santini Alexander A | EVP and CCO | Buy | 745 | $9.78 | $7,286 | No |
| 2017-11-17 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 180,727 | $10.11 | $1,826,896 | No |
| 2017-11-15 | COATS LONNEL | President and CEO | Buy | 10,000 | $9.91 | $99,100 | No |
| 2017-11-14 | Invus Public Equities, L.P. | 10%-Owner, Director | Buy | 575,946 | $9.64 | $5,554,166 | No |
Insider Smart
Insider Smart